Global Blood Transfusion Diagnostics Market is valued at approximately USD 4.6 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.9% over the forecast period 2024-2032. Blood transfusion diagnostics are a critical process involving the testing of both the patient and the blood donor to ensure compatibility before a transfusion. This process includes determining blood types (ABO and Rh), identifying antibodies in the patient's blood, and checking for infectious diseases to prevent adverse reactions and ensure the safe and effective administration of blood products.

The increasing global prevalence of blood disorders, a rise in road accidents and surgeries, and the surge in the global geriatric population are significantly driving the demand for safe transfusion blood. Blood transfusion diagnostics play a crucial role in ensuring donor-recipient compatibility and screening for infections that might be present in blood. The rise in blood disorders like leukemia, thalassemia, sickle cell anemia, and hemophilia is further propelling the market growth. In 2023, an estimated 59,610 new leukemia cases were diagnosed in the U.S., with 23,710 deaths attributed to leukemia, according to the Leukemia and Lymphoma Society. The World Health Organization (WHO) estimates that 5% of the global population are carriers of trait genes for hemoglobin disorders, specifically thalassemia and sickle cell anemia, with over 300,000 infants born with severe hemoglobin disorders annually.

However, inherent challenges with automation dispensing systems and complexities in compatibility testing are the key factors that are substantially halting the growth of the market globally. Moreover, the rising technological innovations in blood donor management systems have brought significant changes to the industry. Automated systems have streamlined workflows, making them more efficient and error-free. Companies have introduced cutting-edge software and mobile applications to enhance donor engagement, scheduling appointments, sending reminders, and offering post-donation care instructions. Advanced management systems and cloud-based technologies have enabled secure storage and easy retrieval of donor information, improving traceability from donor to recipient, and thus offering lucrative opportunities in the blood transfusion diagnostics market.

The blood transfusion diagnostics market segmentation based on product type includes instruments and kits and reagents. Kits and reagents are essential for conducting various pre-transfusion tests such as ABO blood typing, Rh typing, extended phenotyping, RBC antibody screening, and serological and molecular disease screening, driving the growth of this segment.

The key regions considered for the global blood transfusion diagnostics market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America held a dominant market share in 2023 due to advancements in healthcare infrastructure, increased awareness, and augmented healthcare finances. The U.S. sees significant demand for automated pill dispensers from the home healthcare segment, driven by a growing aging population. In March 2024, Roche received U.S. FDA approval for its cobas Malaria test for use on the cobas 6800/8800 Systems, aimed at reducing the potential risk of malarial infection from transfused blood products. In Asia Pacific, the expansion of the market at the highest CAGR is ascribed to the steep increase in major blood-related disorders in countries such as Japan, India, and China, coupled with the rise in adoption of automated instruments for diagnostics and entry of multinational firms within the marketplace.

Major market players included in this report are:
Grifols, S.A.
F. Hoffmann-La Roche Ltd.
Abbott
Bio-Rad Laboratories, Inc.
Werfen, S.A.
QuidelOrtho Corporation
AliveDx Holdings Finance Company Ltd
BAG Diagnostics GmbH
Diasorin S.p.A.
Prestige Diagnostics U.K. Ltd.
Atlas Medical GmbH
Lorne Laboratories Limited
Ortho Clinical Diagnostics
Quotient Limited
Beckman Coulter Inc.
The detailed segments and sub-segment of the market are explained below:
By Product Type:
Instruments
Kits and Reagents
By Application:
Blood Grouping
Disease Screening
By End-user:
Blood Banks
Blood Donation/Transfusion Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.